Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation

Molecular dynamics simulations were carried out for the mutant oseltamivir-NA complex, to provide detailed information on the oseltamivir-resistance resulting from the H274Y mutation in neuraminidase (NA) of avian influenza H5N1 viruses. In contrast with a previous proposal, the H274Y mutation does not prevent E276 and R224 from forming the hydrophobic pocket for the oseltamivir bulky group. Instead, reduction of the hydrophobicity and size of pocket in the area around an ethyl moiety at this bulky group were found to be the source of the oseltamivir-resistance. These changes were primarily due to the dramatic rotation of the hydrophilic –COO− group of E276 toward the ethyl moiety. In addition, hydrogen-bonding interactions with N1 residues at the -NH3+ and -NHAc groups of oseltamivir were replaced by a water molecule. The calculated binding affinity of oseltamivir to NA was significantly reduced from −14.6 kcal mol−1 in the wild-type to −9.9 kcal mol−1 in the mutant-type.

[1]  R. Brüschweiler,et al.  Dynamic and structural analysis of isotropically distributed molecular ensembles , 2002, Proteins.

[2]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[3]  R. Laatikainen,et al.  Correlative motions and memory effects in molecular dynamics simulations of molecules: principal components and rescaled range analysis suggest that the motions of native BPTI are more correlated than those of its mutants. , 2002, Biophysical chemistry.

[4]  Barry Honig,et al.  Extending the Applicability of the Nonlinear Poisson−Boltzmann Equation: Multiple Dielectric Constants and Multivalent Ions† , 2001 .

[5]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[6]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo , 2007, Journal of Virology.

[7]  Thanyada Rungrotmongkol,et al.  Understanding of known drug‐target interactions in the catalytic pocket of neuraminidase subtype N1 , 2008, Proteins.

[8]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  A. Moscona,et al.  Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.

[10]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[11]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[12]  Phillip Andrew Reece,et al.  Neuraminidase inhibitor resistance in influenza viruses , 2007, Journal of medical virology.

[13]  T. Darden,et al.  The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .

[14]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[15]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[16]  J. Järv,et al.  Modeling of the Amino Acid Side Chain Effects on Peptide Conformation , 1999 .

[17]  A. Ferrari,et al.  Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. , 2007, Bioorganic & medicinal chemistry.

[18]  Julian Tirado-Rives,et al.  Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. , 2002, Journal of medicinal chemistry.

[19]  J. Oxford,et al.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. , 2002, Antiviral research.

[20]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[21]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[22]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.

[23]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[24]  J. McKimm-Breschkin,et al.  Mechanisms of resistance of influenza virus to neuraminidase inhibitors , 2001 .

[25]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[26]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors , 2007, Nature Reviews Drug Discovery.

[27]  Marcela Madrid,et al.  Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. , 2005, Journal of the American Chemical Society.

[28]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[29]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[30]  K. Sharp,et al.  Calculating the electrostatic potential of molecules in solution: Method and error assessment , 1988 .

[31]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[32]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[33]  G. Boivin,et al.  Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[35]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[36]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[37]  T. B. Usman,et al.  Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir , 2007, Emerging Infectious Diseases.

[38]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.